|Home||About Us||Resources||Archive||Free Reports|
Saturday, May 23, 2015
The Weekend Edition is pulled from the daily Stansberry Digest. The Digest comes free with a subscription to any of our premium products.
The European Central Bank (ECB) is speeding up its quantitative easing (QE) program...
Since the ECB began QE in March, it has been buying 60 billion euros of bonds each month.
But in a speech earlier this week, ECB Executive Board member Benoit Coeure said the central bank will "front load" the program in May and June – by buying even more than 60 billion euros of bonds each month – to make up for an expected "low liquidity" period during the slow summer months. He said the bank may also "back load" with bigger bond purchases in September.
Coeure said the recent plunge in European bonds is "no cause for concern," but that the "rapidity of the reversal" was worrying. He also claimed the announcement was not intended to calm the recent volatility in European markets before the summer slowdown in trading, but that's exactly the effect it had...
European stocks and bonds rallied on the news, while the euro tumbled as much as 1.6%.
Coeure didn't say how big the "front loaded" purchases would be, but the takeaway is clear: ECB head Mario Draghi and his team are committed to doing whatever it takes to engineer their own version of the "Bernanke Asset Bubble" in Europe. The table is set for a massive rally in European stocks.
Back in the U.S., data this week showed new home construction surged last month to the highest levels in seven years. Housing starts increased 20.2% to a 1.14 million annualized rate, the highest since November 2007.
Our colleague Paul Mampilly isn't surprised. He thinks this trend is just getting started...
Paul explained that it's not just that we haven't been building enough new homes... existing homes are getting old...
And he thinks there are still plenty of opportunities to profit from this trend...
Of course, Paul isn't the only Stansberry Research analyst bullish on housing...
As we've mentioned many times, Steve Sjuggerud was one of the first analysts anywhere to turn bullish on housing. And he's still bullish today.
In fact, Steve thinks housing is the best place to invest in the U.S. today. In the May issue of True Wealth, he explained why...
A quick note to end today's essay...
You may have heard by now that we've launched a brand-new trading service called the Professional Speculator (out Thursday)...
Done right, speculating can lead to life-changing gains. But for most people, it's nearly impossible to profit on a consistent basis. Sure, you might get lucky here and there... But doing it over and over requires far more than luck.
That's why we are thrilled to partner with Paul Mampilly, who has a proven track record of successful speculation. Since 2008, Paul has quintupled his net worth through small, little-known stocks. He has booked gains of 2,539% on a company called AVI BioPharma... 696% on ARIAD Pharmaceuticals... and 355% on Exact Sciences, to name just a few.
Paul doesn't have to work for a living anymore. But we're excited that he agreed to write for Stansberry Research. And we think Professional Speculator could end up being one of the most successful trading advisories in our industry.
Until recently, you would have never had access to Paul's expertise (unless you were a high-net-worth individual who invested with Kinetics Asset Management, the $25 billion fund he used to co-manage).
But now, you'll be able to profit from all of Paul's best recommendations. You'll have a chance to get in on little-known companies with early stage breakthroughs... companies with hundreds-of-percent upside. And Paul – who won the Templeton Foundation investment competition in 2009 – will lead the way.
Paul has been waiting for a chance to recommend a little-known company that he predicts could revolutionize medicine and make you up to 26 times your money over the next decade. That would turn every $5,000 stake into $130,000. Right now, you can get started on a SIX-MONTH risk-free trial subscription to Professional Speculator. And because this service is brand-new, we're offering something incredible: You can get Professional Speculator for
Editor's note: As we noted, we are thrilled to have Paul Mampilly as part of the Stansberry Research team. He brings along an incredible track record and more than 20 years of investment experience.
And right now, Paul has found one of the best speculations he has ever come across. This company has developed what could be the biggest medical breakthrough of the next decade. You can gain immediate access to this pick – as well as his other triple-digit-upside opportunities – with a risk-free trial subscription to the Professional Speculator. Click here to learn more.
Date Range:5/14/2015 to 5/21/2015
Date Range:5/14/2015 to 5/21/2015